FedSoc Forums Courthouse Steps Decision: FDA v. AHM
Jun 24, 2024
57:51
In November 2022, the Alliance Defending Freedom (ADF) filed a federal lawsuit in the U.S. District Court for the Northern District of Texas, Amarillo Division, against the United States Food and Drug Administration (FDA) on behalf of the Alliance of Hippocratic Medicine (AHM) and others.
The suit challenged the FDA’s 2000 decision to legalize mifepristone and misoprostol, two drugs often used in conjunction as chemical abortifacients, and regulation of the drugs thereafter. The case rose through the Fifth Circuit, which ruled in favor of AHM. The Supreme Court granted cert, heard Oral Argument on March 26, 2024, and on June 13, 2024, issued a 9-0 decision holding the plaintiffs lacked standing to challenge the FDA.
Join us for a Courthouse Steps Decision program, where we will analyze this decision and its possible ramifications.
Featuring:
Adam Unikowsky, Partner, Jenner & Block LLP
Megan M. Wold, Partner, Cooper & Kirk
(Moderator) Prof. Teresa Stanton Collett, Professor and Director, Prolife Center, University of St. Thomas School of Law
The suit challenged the FDA’s 2000 decision to legalize mifepristone and misoprostol, two drugs often used in conjunction as chemical abortifacients, and regulation of the drugs thereafter. The case rose through the Fifth Circuit, which ruled in favor of AHM. The Supreme Court granted cert, heard Oral Argument on March 26, 2024, and on June 13, 2024, issued a 9-0 decision holding the plaintiffs lacked standing to challenge the FDA.
Join us for a Courthouse Steps Decision program, where we will analyze this decision and its possible ramifications.
Featuring:
Adam Unikowsky, Partner, Jenner & Block LLP
Megan M. Wold, Partner, Cooper & Kirk
(Moderator) Prof. Teresa Stanton Collett, Professor and Director, Prolife Center, University of St. Thomas School of Law